↓ Skip to main content

Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Behçet’s Disease

Overview of attention for article published in Drugs in R&D, November 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

blogs
1 blog
wikipedia
7 Wikipedia pages

Citations

dimensions_citation
87 Dimensions

Readers on

mendeley
34 Mendeley
Title
Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Behçet’s Disease
Published in
Drugs in R&D, November 2012
DOI 10.2165/00126839-200304010-00002
Pubmed ID
Authors

Takahide Matsuda, Shigeaki Ohno, Shunsei Hirohata, Yoshitaka Miyanaga, Hiroshi Ujihara, Goro Inaba, Satoshi Nakamura, Shun-ichi Tanaka, Mitsuko Kogure, Yutaka Mizushima

Abstract

Behçet's disease (BD) is a recurrent inflammatory disease involving chronic recurrent oral aphthous ulcers (aphthae), uveitis, skin lesions and genital ulcers. We prospectively investigated the efficacy of rebamipide, a gastroprotective drug, against oral aphthous ulcers in BD patients.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 18%
Researcher 5 15%
Other 4 12%
Professor 3 9%
Lecturer 2 6%
Other 6 18%
Unknown 8 24%
Readers by discipline Count As %
Medicine and Dentistry 15 44%
Pharmacology, Toxicology and Pharmaceutical Science 6 18%
Social Sciences 1 3%
Arts and Humanities 1 3%
Unknown 11 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 August 2019.
All research outputs
#4,312,846
of 25,374,917 outputs
Outputs from Drugs in R&D
#79
of 371 outputs
Outputs of similar age
#40,780
of 286,193 outputs
Outputs of similar age from Drugs in R&D
#29
of 122 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 371 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,193 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 122 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.